Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia.

Wiegman, Albert; Gaudet, Daniel; Ruzza, Andrea; Hovingh, G Kees; Santos, Raul D; Mach, François; Stefanutti, Claudia; Luirink, Ilse K; Bridges, Ian; Wang, Bei; Bhatia, Ajay K; Raal, Frederick J; Kastelein, John J P

doi:10.1093/eurjpc/zwae369

Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia.

2026-07-14, European journal of preventive cardiology (10.1093/eurjpc/zwae369) (online)
Albert Wiegman, Daniel Gaudet, Andrea Ruzza, G Kees Hovingh, Raul D Santos, François Mach, Claudia Stefanutti, Ilse K Luirink, Ian Bridges, Bei Wang, Ajay K Bhatia, Frederick J Raal, and John J P Kastelein (?)

Children with heterozygous familial hypercholesterolaemia (HeFH) show greater carotid intima-media thickness (cIMT). Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibody, substantially reduced LDL cholesterol (LDL-C) in children with HeFH. We investigated evolocumab's effect on cIMT progression.

This article has not yet been included in any curations.

Comments

There are no comments on this article yet.

You need to login or register to comment.

BioSothis

Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia.